

# INSIDER



**Dr. W. Kimryn Rathmell,**  
Former Director of the  
National Cancer Institute,  
Named Next CEO of the  
OSUCCC – James



Read the feature on  
Ohio State Health  
& Discovery

## → LETTER FROM THE CEO

# FRIENDS OF PELOTONIA,

We're partway through the season, and it's already shaping up to be an incredible year. The energy, passion, and unity across the Pelotonia community is inspiring. People from all walks of life are finding common ground through Pelotonia's mission. This momentum is a testament to your dedication and the shared belief that we are stronger together.

I'm thrilled to share the exciting news of Dr. W. Kimryn Rathmell's appointment as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Having spent time with Dr. Rathmell in recent months, I am inspired by her humility, vision, and steadfast values. Her leadership, based on collaboration and empathy, will build upon the world-class leadership at the institution and drive significant progress in cancer research.

I am deeply encouraged by the determination and ingenuity of our researchers at the OSUCCC – James, where the

commitment to advancing cancer research remains as strong as ever. With help from Pelotonia funding, the OSUCCC – James is attracting top talent who are leading the charge toward a cancer-free world. In addition to new researchers joining, we've seen new grants awarded, innovative projects launched, and a community that continues to rally together to support progress when it matters most.

Your advocacy and generosity are more vital than ever, ensuring that lifesaving research continues despite the obstacles. Together, we are making progress – one mile, one discovery, and one story at a time.

Thank you for your unwavering commitment.

With deep gratitude,



**Joe Appgar**

CHIEF EXECUTIVE OFFICER  
PELOTONIA

—  
Cancer Survivor




→ EVENT SPOTLIGHT

# PELOTONIA COMMUNITY REFLECTS ON 2024, RECONNECTS AND REIGNITES FOR RIDE YEAR 2025

From honoring major milestones to unveiling new additions, Pelotonia’s recent events energized the community, spotlighted innovation, and set the tone for an impactful year ahead.

Pelotonia closed the 2024 season and promptly kicked off the 2025 season with three dynamic events that showcased the heart and drive of its community. Night of Impact, Pelotonia Summit, and the High Roller Evening of Appreciation each celebrated exciting milestones — from recognizing the individuals who raised an incredible \$26.2 million last year, to introducing bold new initiatives for 2025.

One exciting addition to Pelotonia 2025 was announced in March: O.A.R. will headline Opening Ceremony this year. Mark your calendars and get ready to rock and roll into Ride Weekend!



## NIGHT OF IMPACT NOVEMBER 20, 2024

The Pelotonia community came together at Kemba Live! to reflect on a year marked by determination, generosity, and hope. The celebration honored not only one of the most successful fundraising campaigns in Pelotonia’s history, the third-highest annual total to date, but also the powerful stories of progress from the OSUCCC – James, where groundbreaking research funded by Pelotonia dollars continues to drive life-changing discoveries.

The evening’s celebration began with live music from SWAGG, setting an energizing tone for the night. It then featured remarks from David E. Cohn, MD, a gynecologic oncologist who serves as chief operating officer and chief medical officer at The James Cancer Hospital and Solove Research Institute, and Joe Appar, CEO of Pelotonia. Six remarkable individuals from the Pelotonia community were also honored with Pelotonia Awards, recognizing their outstanding contributions in 2024. The awards, which include First-Year Rider Award, Pelotonia Legacy Award, Volunteer of the Year, Mary Hyatt Courage Award, and Pelotonia-Funded Researcher of the Year, celebrated the passion and perseverance that define the Pelotonia mission.

The evening concluded when nine members of the Pelotonia community — including First-Year Riders, High Rollers, Survivors, and Pelotonia-funded researchers — took the stage to unveil the 2024 fundraising total, a powerful reminder of what’s possible when a community comes together with purpose. The reveal was followed by a celebratory balloon and confetti drop, along with cold spark fireworks on stage.

In 2024, the Pelotonia community celebrated raising an astounding \$26,200,095. Since 2009, more than \$309 million has been raised for innovative cancer research at the OSUCCC – James.



## PELOTONIA SUMMIT JANUARY 29, 2025

Pelotonia Summit kicked off the new year with an exciting gathering of funding partners and Peloton captains, all coming together to prepare for another impactful year. Attendees enjoyed refreshments and appetizers, networked, and built excitement for the upcoming year's events — all while exploring the new Pelotonia Headquarters, which relocated in November to the Energy Advancement and Innovation Center (EAIC) within the Carmenton district of The Ohio State University campus next to the Pelotonia Research Center.

Dr. Zobeida Cruz-Monserrate, the 2024 Pelotonia-Funded Researcher of the Year, shared her journey to The Ohio State University, her involvement with Pelotonia, and its support of her groundbreaking work in pancreatic cancer research.

"I want to express my gratitude to the Pelotonia community. Your selfless contributions of time and energy have made a profound impact. Because of you, we are making meaningful strides toward a future free from disease," she said.

Pelotonia staff revealed the 2025 theme, "Together as One." This represents the collective effort to accelerate the fight against cancer, while inspiring communities to move boldly for the greater good. Guests received exclusive access to 2025 car magnets and yard signs to display in their communities and build excitement.

Next, key registration dates and exciting additions for 2025 were unveiled, including the introduction of a Trail Run/Hike option for participants at Gravel Day.

As Pelotonia Summit concluded, community members left ready to fuel a record-breaking year, while rallying together to further Pelotonia's mission.

## HIGH ROLLER EVENING OF APPRECIATION FEBRUARY 24, 2025

High Rollers are Pelotonia's top individual fundraisers, each committing to raise at least \$5,000 to support innovative cancer research. This dedicated community sets ambitious goals, pushing themselves and their supporters to make a meaningful impact.

High Rollers receive exclusive perks, including a special jersey and an invitation to the High Roller Evening of Appreciation the following year. In 2024, there were 705 High Rollers, and more than 400 attended the celebration at The Bluestone.

Attendees were treated to a delicious array of appetizers and drinks curated by some of Columbus' most celebrated chefs and restaurants. The lineup included Agni and Joyas, led by head chef Avishar Barua, and Chapman's Eat Market and Ginger Rabbit, led by head chef BJ Lieberman — both of whom were present at the event. Guests also enjoyed a lively music performance by the Tom Krouse Band, led by 11-Year Pelotonia participant and former Donatos Pizza CEO, Tom Krouse.

Tanny Crane, the 2024 top individual fundraiser and a 17-Year Rider, shared inspiring remarks about her once-in-a-lifetime cross-country cycling journey, raising awareness for Pelotonia. She encouraged others to embark on their own life-changing adventures in support of the mission.

Guests also heard from Dr. Jeff Patrick, who shared news of a first-in-human clinical trial for a cancer-fighting drug developed entirely at Ohio State — a breakthrough made possible, in part, through Pelotonia funding. You can read more about this development on Page 7.

The 2024 High Roller Night of Appreciation was a powerful reminder of the extraordinary individuals who make the Pelotonia community so special.

# HUNTINGTON AMPLIFIES PELOTONIA'S MISSION WITH VENDOR ENGAGEMENT

*Fundraising event unites vendors from across industries to showcase the impact of cancer research support*

**Since joining Pelotonia's mission in 2009, Huntington Bank has raised more than \$45 million for innovative cancer research – a remarkable achievement resulting from forward-thinking strategies that reach far beyond traditional donation drives.**

For years, Huntington fostered relationships with vendors through classic fundraising events such as charity shoots and golf outings. While these events built a strong foundation, the bank recognized the need to create deeper, more meaningful connections. In 2024, Huntington introduced a new initiative designed to unite vendors from across the country and a wide range of industries – including technology, finance, security, real estate, and creative strategy – behind Pelotonia's mission and highlight the tangible impact of Huntington's support.

The inaugural Huntington Pelotonia Night of Impact Partner Event marked a significant evolution in engagement. Vendors and leaders from both Huntington and Pelotonia gathered for an evening that blended inspiration, education, and action. The event featured a panel discussion with Joe Apgar, CEO of Pelotonia, and Dr. John Warner, CEO of The Ohio State University Wexner Medical Center, providing insights into the latest advancements in cancer research. Attendees also enjoyed

exclusive, behind-the-scenes tours of the OSUCCC – James Pelotonia Institute for Immuno-Oncology and the Medical Modeling, Materials and Manufacturing (M4) labs, offering a firsthand look at the groundbreaking work their contributions support.

At the event, Huntington invited vendors to join Team Huntington through tiered commitment levels, which included opportunities to ride and attend the Huntington Rally, a gathering held before Pelotonia's Opening Ceremony each year that brings colleagues from across the country together to celebrate their collective efforts and kick off Ride Weekend. The inaugural event was considered a resounding success, raising more than


\$750,000 for innovative cancer research.

Building on the momentum of its first Night of Impact, Huntington hosted the event again in 2025, setting an ambitious new goal: to raise \$1.5 million from vendors – doubling the previous year's achievement. This bold target reflected both the growing enthusiasm among vendors and the urgent need to accelerate progress against cancer.

The 2025 event offered an even more immersive experience to a wider audience, doubling the invitation list to more than 30 vendor companies. Attendees heard a welcome from Steve Steinour, Chairman, President, and CEO of Huntington Bancshares Inc., followed by a fireside chat with Joe Apgar and Dr. Glen Barber, director



PICTURED: Huntington CFO Zach Wasserman moderates a research impact panel with Dr. Sameek Roychowdhury and Dr. Gina Sizemore at the second annual Huntington Pelotonia Night of Impact held in April.



**“AT HUNTINGTON, WE BELIEVE IN THE POWER OF PARTNERSHIP TO DRIVE PURPOSE. BY ENGAGING WITH OUR VENDORS, WE’RE ABLE TO AMPLIFY THE MISSION OF PELOTONIA—ACCELERATING CANCER RESEARCH AND BRINGING HOPE TO COUNTLESS LIVES. EACH OF THESE COLLABORATORS PLAYS A VITAL ROLE IN HELPING US MOVE FURTHER, FASTER, TOGETHER.”**

**ZACH WASSERMAN**  
CHIEF FINANCIAL OFFICER,  
HUNTINGTON BANK

**“PELOTONIA IS INTEGRAL TO OUR CULTURE BECAUSE IT BRINGS US TOGETHER FOR A CAUSE GREATER THAN OURSELVES. IT UNITES US IN THE FIGHT AGAINST CANCER AND DEMONSTRATES HOW MUCH WE CAN ACCOMPLISH AS PARTNERS.”**

**BRANT STANDRIDGE**  
SENIOR EXECUTIVE VICE PRESIDENT AND PRESIDENT,  
CONSUMER AND REGIONAL BANKING,  
HUNTINGTON BANK



of the Center for Innate Immunity and Inflammation and globally renowned researcher. Throughout dinner, Huntington executives and the OSUCCC – James researchers joined each table, fostering meaningful conversations about the real-world impact of vendor support. A panel discussion, moderated by Huntington CFO Zach Wasserman, featured Dr. Sameek Roychowdhury, a medical oncologist and member of the Translational Therapeutics Program at the OSUCCC – James, and a professor in the Department of Internal Medicine and the Department of Pharmacology at Ohio State, and Dr. Gina Sizemore, co-leader of the Cancer Biology Program at the OSUCCC – James and an associate professor in the Department of Radiation Oncology

at Ohio State, who shared stories of how Pelotonia funding is transforming cancer research and treatment.

The second annual event closed with the same call to action, asking business vendors to join Huntington in supporting Pelotonia. Since the April event, vendors have already pledged significant support for 2025, further fueling Team Huntington’s impact.

In 2024, Team Huntington raised \$4.2 million through the combined efforts of more than 2,700 participants, including nearly 200 business vendors. This incredible feat demonstrates the power of collaboration and shared purpose in the fight against cancer. So far in 2025, Team Huntington has rallied more than 2,800 participants and raised more than \$938,000 toward innovative cancer research and counting.

# OHIO STATE RECRUITS RENOWNED RESEARCHER

*Dr. Glen Barber builds on groundbreaking discovery that may lead to new treatments for cancer and inflammation*



In connection to funds raised by the Pelotonia community, Glen Barber, PhD, FRS, a globally distinguished immunologist, was recruited to join the OSUCCC – James’ Pelotonia Institute for Immuno-Oncology (PIIO) as director of the Center for Innate Immunity and Inflammation. His groundbreaking work focuses on the body’s innate immune system, which is considered to be the first line of defense against diseases.

A pivotal achievement of Dr. Barber’s team is the discovery of a signaling pathway controlled by a molecule called STING (Stimulator of Interferon Genes) that is activated by microbes such as viruses, bacteria and parasites. This finding has sparked efforts to design drugs that strengthen the body’s immune system by boosting the STING pathway, which is important for generating antitumor immunity.

“Our goal is to design drugs that stimulate innate immunity and test them in new clinical trials,” Dr. Barber explains.

Dr. Barber’s research also explores

the development of vaccines that target viruses linked to cancers. Supported by the National Cancer Institute, these efforts strive to prevent virus-induced cancers through innovative immunological strategies.

Beyond the lab, Dr. Barber is inspired by the community’s commitment to cancer research, exemplified by Pelotonia. He arrived at Ohio State just a day before Ride Weekend 2024, but he’d had his bicycle shipped from Florida to Columbus and joined the Pelotonia community on the 20-mile route the next day.

He shares the OSUCCC – James’ vision of creating a cancer-free world.

“I think it’s possible because there’s so much more to learn, and that means so much opportunity to design ways to combat malignancy,” he explains. “We’re still scratching the surface to a certain extent, but the more we learn through the investment of donors, grants and the cancer center itself, the more team science we can generate



“Pelotonia is incredible. It’s had a massive impact on bringing international recognition to Ohio State and The James, and to bringing in top scientists and physicians who have made this a world-class cancer center that can offer novel treatments to patients around the globe.”

– GLEN BARBER, PHD, FRS

Director of the Center for Innate Immunity and Inflammation at the OSUCCC – James’ PIIO

and the more trials we can offer. Never say never.”

With a legacy of discovery and a vision for a cancer-free future, Dr. Barber continues to push the boundaries of immunology to develop transformative treatments.

## The James



Read the full article on  
Health & Discovery

---

## The Journey of a New Cancer Drug: From Discovery to Patient Care

### DISCOVERY & EARLY DEVELOPMENT (2017–2020)

- In 2017, Ohio State scientists began testing molecules devised by students at Hendrix College to see if any of the molecules had clinical potential.
- In 2019, Sandip Vibhute, PhD, developed the compound known as HOSU-53 in the OSUCCC – James Drug Development Shared Resource.
- Despite COVID-19 delays, by late 2020 the compound was confirmed to have best-in-class potential for blocking a cancer-related enzyme.

### TESTING & FDA APPROVAL (2020–2023)

- Between 2020 and 2023, the drug was tested on various cancers, and a unique marker was found to track its effect.
- Safety tests were completed, and a large application was submitted to the FDA.
- The FDA approved the drug for its first human trial – a big achievement for a university team.

### GETTING TO PATIENTS (2024–2025)

- In 2024, the drug was renamed JBZ-001 and licensed to Jabez Biosciences.
- Early 2025 saw the start of the first clinical trial of the new drug at the OSUCCC – James, offering hope to patients with few options.

---

**“This is a testament to the investment in team, knowledge and infrastructure Ohio State has made to ensure we can propel promising discoveries from the lab to the clinic.”**

#### –JEFF PATRICK, PHARM D

Clinical pharmacist and Senior Director of the Drug Development Institute at the OSUCCC – James

### → RESEARCH SPOTLIGHT

# LOCALLY DEVELOPED CANCER DRUG MOVES TO CLINICAL TRIAL



A powerful new cancer-fighting drug, developed entirely at The Ohio State University, is now entering its first human clinical trial, offering new hope for patients with advanced cancers who have exhausted other options.

This potential breakthrough, known as HOSU-53 during testing and now JBZ-001, was discovered and advanced from lab to clinic by researchers at the OSUCCC – James. Unlike many academic discoveries that are licensed early, Ohio State carried this one through the entire development process — a rare feat — before partnering with a commercial sponsor for clinical testing.

The oral drug works by blocking a key enzyme that cancer cells rely on to grow. “The goal is to starve the cancer while sparing healthy cells,” says Chad Bennett, PhD, one of the lead scientists behind the drug. The treatment has shown promise in lab models against a wide range of cancers, including non-Hodgkin lymphomas and solid tumors.

This success story began with a small collaboration and grew into a large-scale, multi-year effort supported by teams across Ohio State. It was

powered by critical philanthropic funding from partners like Pelotonia and foundations deeply committed to cancer research.

Now, with a phase I trial open at the OSUCCC – James, this drug could make an immediate impact for patients, and it marks a milestone in Ohio State’s mission to bring lifesaving discoveries from the lab to the bedside.

“This study has the potential to immediately help some patients for whom previous therapies have failed. This is the goal of clinical trials in medicine,” says Sebastian Biglione, PhD, PharmD, director of clinical and regulatory strategy for the Drug Development Institute.

---

## The James



Read more in the cover story of **Frontiers** magazine from the OSUCCC – James



→ RESEARCHER SPOTLIGHT

## PELTONIA SCHOLAR EXCELS IN MED SCHOOL, RESEARCH, AND IRONMAN

“Anything is possible.” That mantra drives Matthew Marquardt, a third-year medical student at The Ohio State University College of Medicine, dedicated cancer researcher and Pelotonia Scholar, Pelotonia Rider, and professional Ironman triathlete.

Matthew serves as peloton team captain of the BSR–Spin Doctors under the Team Buckeye super peloton and will ride the 100-mile route during Ride Weekend 2025. As a four-year Rider and High Roller, he has made a significant commitment to innovative cancer research at the OSUCCC – James, raising nearly \$20,000 during his years of Pelotonia participation.

“I ride in Pelotonia because I want to be a part of creating a cancer-free world. This mission is deeply personal to me,” says Matthew, who honors loved ones affected by cancer by writing their initials on his bike — a symbolic reminder of why he rides.

A 2021 graduate of Princeton University with a degree in chemistry (*magna cum laude*) and a minor in entrepreneurship, Matthew hopes to become a head and neck cancer surgeon. At the OSUCCC – James, he is involved in three projects that combine medical science, innovation and human performance. His first project,

mentored by Carmen Quatman, MD, PhD, in the Department of Orthopaedics, explores the surgeon-athlete connection, examining how principles from sports science can improve surgical performance. His second project, in collaboration with Kyle VanKoevering, MD, in the Department of Otolaryngology and the Medical Modeling, Materials and Manufacturing (M4) Lab, uses 3D printing to enhance surgical outcomes for head and neck cancer patients.

“Matthew blends the science and art of medicine with engineering and technology — the same mindset he applies to training and racing,” Dr. VanKoevering says.

His third project, with David E. Cohn, MD, a gynecologic oncologist who serves as chief operating officer and chief medical officer at the James Cancer Hospital and Solove Research Institute, explores the use of continuous glucose monitoring during chemotherapy to identify metabolic changes. “He’s one of the most committed and motivated individuals I’ve ever worked with,” Dr. Cohn says.

Matthew’s passion for performance extends far beyond the lab. After discovering triathlon in 2021, he quickly rose through the ranks. He won the overall age-group title at the 2022

“As a Pelotonia-funded researcher, I have witnessed the transformative impact of this support on groundbreaking cancer research. The funding I received has been crucial in my development as a scientist, propelling forward innovative advancements in cancer treatment by using patient-specific 3D printed anatomic models for use in the operating room during cancer surgery.”

– MATTHEW MARQUARDT

Pelotonia Scholar and third-year medical student at The Ohio State University

IRONMAN World Championship in Kona and turned professional in 2023. That year, he earned three podium finishes and the fastest swim split at the IRONMAN World Championship in Nice. In 2024, he continued to excel with three more podiums and a bike course record at IRONMAN Lake Placid — securing a fourth place finish in the IRONMAN Pro Series. In April 2025, he clocked a sub eight-hour performance at IRONMAN Texas, solidifying his top-30 position in the global PTO World Rankings.

“Triathlon is too hard of a sport to do only by yourself — and so is battling cancer,” he says. “There is incredible power in tackling challenges with others and having a purpose beyond oneself that can positively impact lives.”

As he trains, researches and races, Matthew’s path remains clear: pursue purpose, push limits and help end cancer — one mile, one study and one ride at a time.



Read more about Matthew on the OSU College of Medicine blog



Watch this episode of the IRONMAN docuseries to learn more about Matthew’s journey

# ADAM TROY: INSPIRING THE LINDEN COMMUNITY THROUGH PELOTONIA, YOUTH EVENTS, & SERVICE

As a proud Linden resident, Adam Troy is committed to uplifting his community. Adam serves as the Executive Director of the Community of Caring Development Foundation, a nonprofit that invests in the Linden area of Columbus by providing affordable housing, meals, community grants, and academic scholarships.

Adam has used his influence to strengthen the Pelotonia community as well. In addition to being a three-time Rider and Peloton Captain of Team LINDEN and advocate for the Wheels of Color Peloton, Adam is also a cancer survivor, making Pelotonia's mission of ending cancer deeply personal. He urges his Linden community to join him in raising funds for innovative cancer research at the OSUCCC – James.

“Now more than ever the need for cancer research funding is vital,” Adam said, referencing an American Cancer Society journal on cancer statistics. “Black and African Americans have the highest mortality rate of any racial and ethnic group for all cancers combined and for most major cancers.”

“It’s up to us as a community to continue to fund ground-breaking research in order to not slow progress toward our One Goal.”

In just three years, Team LINDEN has raised an impressive total of nearly \$50,000 for Pelotonia.

Beyond his involvement with the Team LINDEN peloton, Adam also played a vital role in launching Pelotonia Kids Linden in 2024. The neighborhood youth event aimed to promote children's health and safety through cycling. It also encouraged kids to focus on fitness while fostering community as they came together to raise funds for innovative pediatric cancer research at Nationwide Children's Hospital and build a brighter future for Columbus youth. Adam brought together additional partners – including philanthropist Renee and

Dwight Smith, founders of the Thanks Be to God Foundation, Designer Shoe Warehouse (DSW), New Salem Baptist Church, We Are Linden, the City of Columbus Department of Neighborhoods and Public Safety, Saint Stephen's Community House, and Columbus City Councilmember Emmanuel Remy – to make the Pelotonia Kids Linden event more impactful. Held in collaboration with the City of Columbus' Public Safety Week, the inaugural event also featured food trucks, resource tables, and a children's bike giveaway.

“Events like this give us hope for a brighter tomorrow, laying the groundwork not only for philanthropy in our youth, but also to inspire them to be future community organizers. It's teaching them the value of service above self,” Adam said.

The next Pelotonia Kids Linden ride is Saturday, August 30, 2025, at Maloney Park in Linden. Scheduled in concert with We Are Linden's 10th Annual Back to School Block Party and planned in collaboration with last year's partners, this year's event will include many of the same fun activities, giveaways, and more. Riders and volunteers are welcomed.



**PELOTONIA®**  
**KIDS**

Learn more at  
[pelotoniakids.com](https://pelotoniakids.com)



# PANFILS PAY IT FORWARD WITH RESEARCH BEQUEST

**“WITHOUT PELOTONIA, THERE ARE NO RESEARCHERS; THERE ARE NO BREAKTHROUGHS.”**

**AMANDA PANFIL, PHD**

PELOTONIA LEGACY SOCIETY MEMBER  
ASSISTANT PROFESSOR IN THE COLLEGE OF VETERINARY MEDICINE AT OHIO STATE  
MEMBER OF THE LEUKEMIA AND HEMATOLOGIC MALIGNANCIES PROGRAM AT THE OSUCCC – JAMES



to cancer research at the OSUCCC – James.

Since joining Ohio State in 2019, Amanda has been a Rider with Team Buckeye. Amanda has seen firsthand the impact of Pelotonia, not only in her own lab, but also in the careers of young scientists she mentors. Three of her trainees have received Pelotonia-funded research scholarships.

For Amanda and Joe, Pelotonia is more than an annual event; it’s a mission and a community united to end cancer. By joining the Pelotonia Legacy Society, the Panfils are helping to secure the future of groundbreaking research, ensuring that progress continues for generations to come. Their philanthropy stands as a testament to the power of hope, science, and community action.

Amanda Panfil, PhD, an assistant professor in the College of Veterinary Medicine at Ohio State, and a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, and her husband Joe have made a lasting commitment to cancer research

by naming Pelotonia as a beneficiary in their estate plans. Their decision reflects a deeply personal connection: Amanda’s research on human viruses that cause cancer has been directly supported by Pelotonia’s unique model, which ensures 100 percent of participant-raised funds go

## PELOTONIA LEGACY SOCIETY



The Pelotonia Legacy Society is a group of forward-thinking supporters who share a vision to provide for future generations of cancer patients and their families.

Planned giving, also known as legacy giving, allows you to have a lasting impact on cancer research while contributing to the long-term stability of Pelotonia’s mission for years to come.

By leaving a planned gift, you commit to contribute to Pelotonia beyond your lifetime – and you will become part of the Pelotonia Legacy Society.

You will receive waived registration fees for Ride Weekend and Gravel Day,

tickets to Opening Ceremony and Night of Impact, and an exclusive Pelotonia Legacy Society lapel pin. Thank you to the community members in the Pelotonia Legacy Society for their generosity and commitment!

Contact Philanthropy & Stewardship Manager, Erika Walker, at [ewalker@pelotonia.org](mailto:ewalker@pelotonia.org) for more information.

### COMMON PLANNED GIVING METHODS

- Bequests
- Life insurance policies
- Retirement plans and IRA rollovers
- Charitable gift annuities

### PELOTONIA PLANNED GIVING WEBINAR

On May 20, Pelotonia was excited to host a special webinar focused on the power of planned giving and how anyone can make a lasting impact on cancer research for generations to come.

This informative and inspirational session featured John Woods, Associate Vice President of Estate and Gift Planning at The Ohio State University, who shared insights into common giving tools like bequests, retirement assets, and life insurance policies. Together, John and Pelotonia staff answered questions from the audience in this interactive webinar.



**ALREADY INCLUDED PELOTONIA IN YOUR ESTATE PLANS? NOTIFY US OF YOUR GIFT BY COMPLETING THIS FORM**



**SCAN TO WATCH A REPLAY OF THE PELOTONIA PLANNED GIVING WEBINAR**

## OUR MISSION

At Pelotonia, we're driven by our mission: to engage, inspire, and challenge a community committed to change the world by accelerating innovative cancer research.

THANKS TO OUR FUNDING PARTNERS,  
100% OF EVERY DOLLAR RAISED IS  
DIRECTED TO INNOVATIVE CANCER  
RESEARCH AT THE OSUCCC – JAMES.

### BENEFITTING

## The James



## MAJOR FUNDING PARTNERS



Bath&BodyWorks®



PEGGY & RICHARD  
SANTULLI

VS&Co  
VICTORIA'S SECRET & CO.

## SUPPORTING FUNDING PARTNERS



THE HASLAM<sup>3</sup>  
FOUNDATION



Safelite

## NOTABLE FUNDING PARTNERS



DIAMOND HILL



## OUR BOARD

**Robert H. Schottenstein**

**BOARD CHAIR**

*Chairman and CEO, M/I Homes, Inc.*

**Doug Ulman**

**VICE CHAIR**

*Senior Advisor to the Pelotonia CEO*

**Carol R. Bradford, MD, MS, FACS**

*Dean, College of Medicine and Vice President for Health Sciences, The Ohio State University Wexner Medical Center*

**Renee Cacchillo**

*President & Chief Executive Officer, Safelite® Group*

**Victor Crawford**

*Board Member at The Hershey Company*

**Cindy Hilsheimer**

*Managing Principal, BeecherHill*

**Peter J. Mohler, PhD**

*Executive Vice President for Research, Innovation and Knowledge, The Ohio State University*

**Raphael E. Pollock, MD, PhD, FACS**

*Director, The Ohio State University Comprehensive Cancer Center*

**Daniel Rosenthal**

*President & CEO, Global Critical Logistics*

**Steve Steinour**

*Chairman, President and CEO, Huntington Bancshares Inc.*

**Abigail Wexner**

*CEO, Whitebarn Associates*

# PELTONIA®

2281 Kenny Road  
Suite 450  
Columbus, OH 43210

[pelotonia.org](http://pelotonia.org)

## PELTONIA INSIDER

ISSUE 3  
SPRING 2025

*Celebrating new innovations in cancer research at the OSUCCC – James made possible in part by Pelotonia funding*

### FEATURED INSIDE:



→ PARTNER SPOTLIGHT:  
**HUNTINGTON AMPLIFIES  
PELTONIA'S MISSION WITH  
VENDOR ENGAGEMENT**

4



→ RESEARCH SPOTLIGHT:  
**LOCALLY DEVELOPED CANCER  
DRUG MOVES TO CLINICAL TRIAL**

7



→ RESEARCHER SPOTLIGHT:  
**PELTONIA SCHOLAR EXCELS  
IN MED SCHOOL, RESEARCH,  
AND IRONMAN**

8

